- Mylonakis, Eleftherios;
- Lutaakome, Joseph;
- Jain, Mamta;
- Rogers, Angela;
- Moltó, José;
- Benet, Susana;
- Mourad, Ahmad;
- Files, D;
- Mugerwa, Henry;
- Kityo, Cissy;
- Kiweewa, Francis;
- Nalubega, Mary;
- Kitonsa, Jonathan;
- Nabenkema, Evelyn;
- Murray, Daniel;
- Braun, Dominique;
- Kamel, Dena;
- Higgs, Elizabeth;
- Hatlen, Timothy;
- Kan, Virginia;
- Sanchez, Adriana;
- Tierney, John;
- Denner, Eileen;
- Wentworth, Deborah;
- Babiker, Abdel;
- Davey, Victoria;
- Gelijns, Annetine;
- Matthews, Gail;
- Thompson, B;
- Lane, H;
- Neaton, James;
- Lundgren, Jens
The protection provided by natural versus hybrid immunity from COVID-19 is unclear. We reflect on the challenges from trying to conduct a randomized post-SARS-CoV-2 infection vaccination trial study with rapidly evolving scientific data, vaccination guidelines, varying international policies, difficulties with vaccine availability, vaccine hesitancy, and a constantly evolving virus.
